The lymphocyte-specific protein tyrosine kinase-specific inhibitor A-770041 attenuates lung fibrosis via the suppression of TGF-β production in regulatory T-cells
Fig 3
A-770041 reduces the percentage of TGF-β-producing CD4+ T-cells in BLM treated lungs.
Mice received a single transbronchial instillation of 3.0 mg/kg BLM on Day 0, and BALF was collected on days 0, 7, 14, and 21. Lymphocyte counts (A) and the CD4/8 ratio (C) in the BALF were examined by flow cytometry (n = 5). The percentages of Il-17+ CD4+ T-cells and TGF-β1+ CD4+ T-cells infiltrating lung tissues were examined by flow cytometry (B, D, E). After BLM treatment, A-770041 (5 mg/kg/day) or vehicle was administered daily, and lungs were collected on day 7 (n = 5). The percentages of Il-17+ CD4+ T-cells and TGF-β1+ CD4+ T-cells infiltrating lung tissues with or without A-770041 were examined by flow cytometry (F, G). The concentration of TGF-β in BALF was examined by an ELISA. *: p<0.05 versus samples of day 7; **: p<0.01 versus samples of day 0; #: p<0.01 versus group treated with BLM without A-770041; ##: p<0.05 versus group treated with BLM without A-770041.